{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T22:54:08Z","timestamp":1788648848727,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"DOI":"10.1186\/s12891-025-08688-8","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T06:44:43Z","timestamp":1746600283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of denosumab in treatment of osteoporosis in patients with rheumatoid arthritis: a meta-analysis of randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Tao","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingwen","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiwei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"8688_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.962969","volume":"9","author":"R Sakthiswary","year":"2022","unstructured":"Sakthiswary R, Uma Veshaaliini R, Chin KY, Das S, Sirasanagandla SR. Pathomechanisms of bone loss in rheumatoid arthritis. Front Med (Lausanne). 2022;9: 962969.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"8688_CR2","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.3390\/ijms23031104","volume":"23","author":"Y Omata","year":"2022","unstructured":"Omata Y, Frech M, Saito T, Schett G, Zaiss MM, Tanaka S. Inflammatory Arthritis and Bone Metabolism Regulated by Type 2 Innate and Adaptive Immunity. Int J Mol Sci. 2022;23(3):1104.","journal-title":"Int J Mol Sci"},{"issue":"10055","key":"8688_CR3","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):1984.","journal-title":"Lancet"},{"key":"8688_CR4","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis Nat Rev Dis Primers. 2018;4:18001.","journal-title":"Rheumatoid arthritis Nat Rev Dis Primers"},{"issue":"160","key":"8688_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0011-2021","volume":"30","author":"S Kadura","year":"2021","unstructured":"Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021;30(160): 210011.","journal-title":"Eur Respir Rev"},{"issue":"4","key":"8688_CR6","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10067-020-05320-z","volume":"40","author":"Y Dai","year":"2021","unstructured":"Dai Y, Wang W, Yu Y, Hu S. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin Rheumatol. 2021;40(4):1211\u201320.\\","journal-title":"Clin Rheumatol"},{"issue":"1","key":"8688_CR7","first-page":"264","volume":"13","author":"T Wang","year":"2024","unstructured":"Wang T, Bi Y, Chen L, et al. Denosumab for the treatment of bone damage in rheumatoid arthritis: a systematic review and meta-analysis. Ann Palliat Med. 2024;13(1):264\u201373.","journal-title":"Ann Palliat Med"},{"issue":"2","key":"8688_CR8","first-page":"202","volume":"75","author":"T Takeuchi","year":"2023","unstructured":"Takeuchi T, Tanaka Y, Matsubara T, et al. Effect of Denosumab on Progressive Bone Loss in Rheumatoid Arthritis Patients Treated With Biological DMARDs: A Phase 3, Randomized. Placebo-Controlled Trial Arthritis Rheumatol. 2023;75(2):202\u201310.","journal-title":"Placebo-Controlled Trial Arthritis Rheumatol"},{"issue":"3","key":"8688_CR9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/mr\/roab001","volume":"32","author":"K Ebina","year":"2022","unstructured":"Ebina K, Miyama A, Hirao M, et al. The effectiveness of denosumab for preventing progression of bone erosion in rheumatoid arthritis: a systematic review and meta-analysis. Mod Rheumatol. 2022;32(3):528\u201333.","journal-title":"Mod Rheumatol"},{"key":"8688_CR10","volume":"223","author":"ZH Li","year":"2021","unstructured":"Li ZH, Fu X, Tang JY, et al. Inhibition of RANKL improves bone erosion and joint destruction in rheumatoid arthritis patients by inhibiting osteoclast differentiation. Clin Immunol. 2021;223: 108647.","journal-title":"Clin Immunol"},{"issue":"1","key":"8688_CR11","first-page":"22","volume":"47","author":"AN Lau","year":"2020","unstructured":"Lau AN, Wong-Pack M, Rodjanapiches R, et al. Occurrence of serious infections in patients with rheumatoid arthritis treated with biologics and denosumab observed in a clinical setting. J Rheumatol. 2020;47(1):22\u201330.","journal-title":"J Rheumatol"},{"issue":"1","key":"8688_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","volume":"8","author":"Q Ding","year":"2023","unstructured":"Ding Q, Hu W, Wang R, et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct Target Ther. 2023;8(1):68.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"8688_CR13","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/rheumatology\/key416","volume":"58","author":"N Ishiguro","year":"2019","unstructured":"Ishiguro N, Tanaka Y, Yamanaka H, et al. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. Rheumatology (Oxford). 2019;58(6):997\u20131005.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"8688_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/mr\/roae002","volume":"34","author":"N Iwamoto","year":"2024","unstructured":"Iwamoto N, Sato S, Furukawa K, et al. Association of denosumab with serum cytokines, chemokines, and bone-related factors in patients with rheumatoid arthritis: A post hoc analysis of a multicentre, open-label, randomised, parallel-group study. Mod Rheumatol. 2024;34(5):936\u201346.","journal-title":"Mod Rheumatol"},{"issue":"8","key":"8688_CR15","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1136\/annrheumdis-2021-219846","volume":"80","author":"H So","year":"2021","unstructured":"So H, Cheng IT, Lau SL, et al. Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2021;80(8):981\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8688_CR16","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3899\/jrheum.201376","volume":"48","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Takeuchi T, Soen S, et al. Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. J Rheumatol. 2021;48(11):1663\u201371.","journal-title":"J Rheumatol"},{"issue":"7","key":"8688_CR17","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/annrheumdis-2018-214827","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi T, Tanaka Y, Soen S, et al. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. Ann Rheum Dis. 2019;78(7):899\u2013907.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8688_CR18","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Tanaka Y, Ishiguro N, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis. 2016;75(6):983\u201390.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8688_CR19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/art.23417","volume":"58","author":"SB Cohen","year":"2008","unstructured":"Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5):1299\u2013309.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"8688_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00774-021-01203-8","volume":"39","author":"H Yasuda","year":"2021","unstructured":"Yasuda H. Discovery of the RANKL\/RANK\/OPG system. J Bone Miner Metab. 2021Jan;39(1):12.","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"8688_CR21","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1007\/s00198-022-06479-8","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022Oct;33(10):2243.","journal-title":"Osteoporos Int"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-025-08688-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-025-08688-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-025-08688-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T09:58:54Z","timestamp":1757757534000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-025-08688-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8688"],"URL":"https:\/\/doi.org\/10.1186\/s12891-025-08688-8","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article was revised: the affiliation 'Department of Orthopedics, The People's Hospital of Longquan, Zhejiang Province, China' was missing for Shuiwei Mao and has now been added. Shuiwei Mao was affiliated with the Department of Orthopedics, The People's Hospital of Longquan, Zhejiang Province, China, at the time of submission.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Civil Aviation General Hospital under acceptance number 2017(MH-003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All human participants provided written informed consent before participation in the study in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"450"}}